My Recent Searches
- No Recent Search.
My Tests Viewed
- No Test Viewed.
RAS Mutation Analysis, Thyroid Cancer
To view specimen requirements and codes please Select a regional laboratory.Not sure which laboratory serves your office? Call us 866-MYQUEST (866-697-8378)
81403, 81311, 81275, 81276
**IMPORTANT: CPT Code is informational only; obtain the Test Code for ordering.
HRAS, KRAS, NRAS
|HRAS Mutation||Not detected|
|KRAS Mutation||Not detected|
|NRAS Mutation||Not detected|
Activating mutations in the RAS genes, particularly NRAS, have been detected in follicular thyroid carcinomas (up to 40%) and papillary thyroid carcinomas (up to 10%), but are also seen commonly in follicular adenomas. Correlation with morphologic and clinical findings is thus required. Follicular thyroid neoplasms with RAS mutations may behave more aggressively than those without. The assay tests for mutations in codon 12 and 13 (exon 1) and codon 61 (exon 2) in HRAS, KRAS and NRAS by a DNA-based sequencing method, with an approximate sensitivity of 1 to 5% mutation-bearing cells in a mixed sample. This assay will not detect RAS mutations outside the codons listed above.
Reference ranges are provided as general guidance only. To interpret test results use the reference range in the laboratory report.
The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
* The tests listed by specialist are a select group of tests offered. For a complete list of Quest Diagnostics tests, please refer to our Directory of Services.